These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 21993678

  • 1. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD.
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [Abstract] [Full Text] [Related]

  • 2. Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.
    Jiang H, Zou J, Zhang H, Fu W, Zeng T, Huang H, Zhou F, Hou J.
    Clin Exp Med; 2015 Feb; 15(1):85-96. PubMed ID: 24356728
    [Abstract] [Full Text] [Related]

  • 3. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
    Xu X, Liu J, Huang B, Chen M, Yuan S, Li X, Li J.
    Tumori; 2017 May 12; 103(3):261-267. PubMed ID: 27647225
    [Abstract] [Full Text] [Related]

  • 4. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
    Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.
    Cancer Cell; 2013 Sep 09; 24(3):289-304. PubMed ID: 24029229
    [Abstract] [Full Text] [Related]

  • 5. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC.
    Blood; 2012 Jun 14; 119(24):5772-81. PubMed ID: 22538852
    [Abstract] [Full Text] [Related]

  • 6. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
    Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH.
    Proc Natl Acad Sci U S A; 2003 Aug 19; 100(17):9946-51. PubMed ID: 12902539
    [Abstract] [Full Text] [Related]

  • 7. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D, McConnell EJ, Dierlam L, Palamarchuk A, Lass A, Wójcik C.
    Int J Cancer; 2007 Jul 15; 121(2):431-41. PubMed ID: 17373661
    [Abstract] [Full Text] [Related]

  • 8. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
    Gu JL, Li J, Zhou ZH, Liu JR, Huang BH, Zheng D, Su C.
    Biochem Biophys Res Commun; 2012 Apr 13; 420(3):644-50. PubMed ID: 22450313
    [Abstract] [Full Text] [Related]

  • 9. [Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
    Yang Y, Dong HJ, Gao GX, Wang YW, Gu HT, Shu MM, Zhu HF, Chen XQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct 13; 18(5):1177-80. PubMed ID: 21129256
    [Abstract] [Full Text] [Related]

  • 10. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
    Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.
    Blood; 2012 Jan 19; 119(3):826-37. PubMed ID: 22128141
    [Abstract] [Full Text] [Related]

  • 11. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ.
    Haematologica; 2016 Mar 19; 101(3):346-55. PubMed ID: 26659919
    [Abstract] [Full Text] [Related]

  • 12. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L, Matějíková J, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S.
    Klin Onkol; 2013 Mar 19; 26(1):11-8. PubMed ID: 23528167
    [Abstract] [Full Text] [Related]

  • 13. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
    Nikesitch N, Tao C, Lai K, Killingsworth M, Bae S, Wang M, Harrison S, Roberts TL, Ling SC.
    Blood Cancer J; 2016 Jun 10; 6(6):e432. PubMed ID: 27284736
    [No Abstract] [Full Text] [Related]

  • 14. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SM.
    Neoplasia; 2022 Jan 10; 24(1):1-11. PubMed ID: 34826777
    [Abstract] [Full Text] [Related]

  • 15. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, Iida S, Nakashima T, Shiotsu Y, Mitsuya H, Hata H.
    Int J Oncol; 2015 Mar 10; 46(3):963-72. PubMed ID: 25530098
    [Abstract] [Full Text] [Related]

  • 16. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH.
    Blood; 2006 Jun 15; 107(12):4907-16. PubMed ID: 16507771
    [Abstract] [Full Text] [Related]

  • 18. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    Iida S, Ri M.
    Rinsho Ketsueki; 2014 Mar 15; 55(3):304-10. PubMed ID: 24681933
    [No Abstract] [Full Text] [Related]

  • 19. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
    Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, Ambinder RF.
    Blood; 2011 Jun 09; 117(23):6297-303. PubMed ID: 21447826
    [Abstract] [Full Text] [Related]

  • 20. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
    Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y, Dong B.
    Leuk Lymphoma; 2009 Jun 09; 50(6):974-84. PubMed ID: 19391038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.